Improving Stroke Outcome Prediction Using Molecular and Machine Learning Approaches in Large Vessel Occlusion

Madhusmita Rout1, April Vaughan2, Evgeny V Sidorov2

  • 1Department of Pediatrics, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

PubMed

Insights

This study reveals that specific circulating miRNAs and metabolites can predict stroke outcomes in large vessel occlusion (LVO) patients. Integrating these molecular markers with clinical data significantly improves prediction accuracy for acute ischemic stroke (AIS).

Area of Science:

  • Biomarkers
  • Neuroscience
  • Metabolomics
  • Genomics

Background:

  • Predicting stroke outcomes in acute ischemic stroke (AIS), particularly with large vessel occlusion (LVO), remains challenging.
  • Current tools like infarct volume and NIHSS have limited accuracy for LVO patients.
  • Blood-brain barrier (BBB) disruption in LVO may cause detectable metabolic and RNA changes.

Purpose of the Study:

  • To determine if metabolic and RNA differences in circulation correlate with infarct size in LVO strokes.
  • To assess if combining molecular markers with clinical/imaging data improves outcome prediction in LVO.

Main Methods:

  • Infarct volume measured by MRI; 90-day outcomes assessed by modified Rankin Scale (mRS).
  • Serum exosome microRNAs (miRNAs) analyzed via RNA sequencing.
  • Metabolites identified using Nuclear Magnetic Resonance (NMR) spectroscopy.

Main Results:

  • 41 miRNAs and 11 metabolites significantly associated with infarct volume.
  • 8 miRNAs and ketone bodies correlated with infarct volume, NIHSS, and mRS.
  • Machine learning integrating clinical, imaging, and omics data achieved 0.81 accuracy and 0.91 AUC for outcome prediction.

Conclusions:

  • Molecular markers (miRNAs, metabolites) offer insights into stroke pathophysiology and outcome.
  • Integrating omics data with clinical and imaging tools enhances predictive accuracy for LVO stroke.
  • This approach provides a framework for improved stroke therapeutics and patient outcomes.